5 stories found
Chinese regulators have granted approval for the subcutaneous injection form of lecanemab (Leqembi) to serve as an initial therapy for patients diagnosed with early-stage Alzheimer's disease.
New Alzheimer's drugs, including Lecanemab and Donanemab, which were initially met with high hopes, have disappointed in a recent study, showing more risks than benefits.
Canada’s national drug agency has issued a final positive recommendation supporting public funding for lecanemab, a treatment for early-stage Alzheimer’s disease.
A research team has confirmed the safety of the Alzheimer's drug Lecanemab after examining health data from 2,672 patients 28 weeks into treatment.
The LEQEMBI IQLIK® (lecanemab-irmb) autoinjector is now available in the U.S. for the initiation of therapy for early Alzheimer’s disease.